Terms: = Head and neck cancer AND ERCC4, XPF, 2072, ENSG00000175595, Q92889 AND Treatment
24 results:
1. Genetic variability in cisplatin metabolic pathways and outcome of locally advanced head and neck squamous cell carcinoma patients.
Ferreira AMC; Altemani JMC; Macedo LT; Lourenço GJ; Lima CSP
Sci Rep; 2023 Oct; 13(1):16762. PubMed ID: 37798436
[TBL] [Abstract] [Full Text] [Related]
2. Human papillomavirus associated xpf deficiency increases alternative end joining and cisplatin sensitivity in head and neck squamous cell carcinoma.
Zuo N; Ma L; Liu T; Hu W; Luo Y; Meng H; Ren Q; Deng Y; Wei L; Liu Q
Oral Oncol; 2023 May; 140():106367. PubMed ID: 36996606
[TBL] [Abstract] [Full Text] [Related]
3. Plasma microRNA-192-5p can predict the response to neoadjuvant chemotherapy and prognosis in esophageal cancer.
Furuke H; Konishi H; Arita T; Kataoka S; Shibamoto J; Takabatake K; Takaki W; Shimizu H; Yamamoto Y; Komatsu S; Shiozaki A; Fujiwara H; Otsuji E
Cancer Sci; 2023 Apr; 114(4):1686-1696. PubMed ID: 36533956
[TBL] [Abstract] [Full Text] [Related]
4. Immunohistochemical expression of TFIIH and xpf in oral tongue squamous cell carcinoma.
Sá MC; Conceição TS; de Moura Santos E; de Morais EF; Galvão HC; de Almeida Freitas R
Eur Arch Otorhinolaryngol; 2020 Mar; 277(3):893-902. PubMed ID: 31828418
[TBL] [Abstract] [Full Text] [Related]
5. The prognostic value of pre-treatment prognostic nutritional index in esophageal squamous cell carcinoma: A meta-analysis.
Li P; Wang X; Lai Y; Zhou K; Tang Y; Che G
Medicine (Baltimore); 2019 May; 98(22):e15280. PubMed ID: 31145271
[TBL] [Abstract] [Full Text] [Related]
6. Association of GSTP1 and ERCC1 polymorphisms with toxicity in locally advanced head and neck cancer platinum-based chemoradiotherapy treatment.
Duran G; Aguín S; Cruz R; Barros F; Giráldez JM; Bernárdez B; López-López R; Carracedo Á; Lamas MJ
Head Neck; 2019 Aug; 41(8):2704-2715. PubMed ID: 30973677
[TBL] [Abstract] [Full Text] [Related]
7. Translational study identifies xpf and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma.
MacGregor TP; Carter R; Gillies RS; Findlay JM; Kartsonaki C; Castro-Giner F; Sahgal N; Wang LM; Chetty R; Maynard ND; Cazier JB; Buffa F; McHugh PJ; Tomlinson I; Middleton MR; Sharma RA
Sci Rep; 2018 May; 8(1):7265. PubMed ID: 29739952
[TBL] [Abstract] [Full Text] [Related]
8. GSTP1 c.313A>G, XPD c.934G>A, xpf c.2505T>C and CASP9 c.-1339A>G Polymorphisms and Severity of Vomiting in head and neck cancer Patients treated with Cisplatin Chemoradiation.
Carron J; Lopes-Aguiar L; Costa EFD; Nogueira GAS; Lima TRP; Pincinato EC; Visacri MB; Quintanilha JCF; Moriel P; Lourenço GJ; Lima CSP
Basic Clin Pharmacol Toxicol; 2017 Dec; 121(6):520-525. PubMed ID: 28686330
[TBL] [Abstract] [Full Text] [Related]
9. Outcome and risk factors assessment for adverse events in advanced esophageal cancer patients after self-expanding metal stents placement.
Rodrigues-Pinto E; Pereira P; Coelho R; Andrade P; Ribeiro A; Lopes S; Moutinho-Ribeiro P; Macedo G
Dis Esophagus; 2017 Feb; 30(3):1-6. PubMed ID: 27629280
[TBL] [Abstract] [Full Text] [Related]
10. Trends in treatment and survival for advanced laryngeal cancer: A 20-year population-based study in The Netherlands.
Timmermans AJ; van Dijk BA; Overbeek LI; van Velthuysen ML; van Tinteren H; Hilgers FJ; van den Brekel MW
Head Neck; 2016 Apr; 38 Suppl 1():E1247-55. PubMed ID: 26315454
[TBL] [Abstract] [Full Text] [Related]
11. Single nucleotide polymorphisms in nucleotide excision repair genes, cancer treatment, and head and neck cancer survival.
Wyss AB; Weissler MC; Avery CL; Herring AH; Bensen JT; Barnholtz-Sloan JS; Funkhouser WK; Olshan AF
Cancer Causes Control; 2014 Apr; 25(4):437-50. PubMed ID: 24487794
[TBL] [Abstract] [Full Text] [Related]
12. ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.
Bauman JE; Austin MC; Schmidt R; Kurland BF; Vaezi A; Hayes DN; Mendez E; Parvathaneni U; Chai X; Sampath S; Martins RG
Br J Cancer; 2013 Oct; 109(8):2096-105. PubMed ID: 24064970
[TBL] [Abstract] [Full Text] [Related]
13. Assessment of ERCC1 and xpf protein expression using quantitative immunohistochemistry in nasopharyngeal carcinoma patients undergoing curative intent treatment.
Jagdis A; Phan T; Klimowicz AC; Laskin JJ; Lau HY; Petrillo SK; Siever JE; Thomson TA; Magliocco AM; Hao D
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1340-5. PubMed ID: 23182703
[TBL] [Abstract] [Full Text] [Related]
14. Validation of genetic sequence variants as prognostic factors in early-stage head and neck squamous cell cancer survival.
Azad AK; Bairati I; Samson E; Cheng D; Mirshams M; Qiu X; Savas S; Waldron J; Wang C; Goldstein D; Xu W; Meyer F; Liu G
Clin Cancer Res; 2012 Jan; 18(1):196-206. PubMed ID: 22076708
[TBL] [Abstract] [Full Text] [Related]
15. DNA repair biomarkers predict response to neoadjuvant chemoradiotherapy in esophageal cancer.
Alexander BM; Wang XZ; Niemierko A; Weaver DT; Mak RH; Roof KS; Fidias P; Wain J; Choi NC
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):164-71. PubMed ID: 22000749
[TBL] [Abstract] [Full Text] [Related]
16. xpf expression correlates with clinical outcome in squamous cell carcinoma of the head and neck.
Vaezi A; Wang X; Buch S; Gooding W; Wang L; Seethala RR; Weaver DT; D'Andrea AD; Argiris A; Romkes M; Niedernhofer LJ; Grandis JR
Clin Cancer Res; 2011 Aug; 17(16):5513-22. PubMed ID: 21737503
[TBL] [Abstract] [Full Text] [Related]
17. Genetic variants in DNA repair predicts the survival of patients with esophageal cancer.
Lee JM; Yang PW; Yang SY; Chuang TH; Tung EC; Chen JS; Huang PM; Lee YC
Ann Surg; 2011 May; 253(5):918-27. PubMed ID: 21490450
[TBL] [Abstract] [Full Text] [Related]
18. treatment of esophageal cancer based on histology: a surveillance epidemiology and end results analysis.
Chang DT; Chapman C; Shen J; Su Z; Koong AC
Am J Clin Oncol; 2009 Aug; 32(4):405-10. PubMed ID: 19415029
[TBL] [Abstract] [Full Text] [Related]
19. Dermatological high-dose-rate brachytherapy for the treatment of basal and squamous cell carcinoma.
Sedda AF; Rossi G; Cipriani C; Carrozzo AM; Donati P
Clin Exp Dermatol; 2008 Nov; 33(6):745-9. PubMed ID: 18681873
[TBL] [Abstract] [Full Text] [Related]
20. Prediction of response to neoadjuvant chemotherapy in carcinomas of the upper gastrointestinal tract.
Höfler H; Langer R; Ott K; Keller G
Recent Results Cancer Res; 2007; 176():33-6. PubMed ID: 17607914
[TBL] [Abstract] [Full Text] [Related]
[Next]
